Search Results - "Ravdin, PM"

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer by OLIVOTTO, Ivo A, BAJDIK, Chris D, RAVDIN, Peter M, SPEERS, Caroline H, COLDMAN, Andrew J, NORRIS, Brian D, DAVIS, Greg J, CHIA, Stephen K, GELMON, Karen A

“…Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not…”
Get full text

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer by JONES, S. E, ERBAN, J, MENNEL, R, RICHARDS, D, OLSEN, S, MEYERS, M. L, RAVDIN, P. M, OVERMOYER, B, BUDD, G. T, HUTCHINS, L, LOWER, E, LAUFMAN, L, SUNDARAM, S, URBA, W. J, PNTCHARD, K. I

“…This randomized, controlled, multicenter, open-label, phase III study compared docetaxel versus paclitaxel in patients with advanced breast cancer that had…”
Get full text

Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer by RAVDIN, Peter M, SIMINOFF, Laura A, DAVIS, Greg J, MERCER, Mary Beth, HEWLETT, Joan, GERSON, Nancy, PARKER, Helen L

“…The goal of the computer program Adjuvant! is to allow health professionals and their patients with early breast cancer to make more informed decisions about…”
Get full text

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial by Albain, K, Gray, RJ, Sparano, JA, Makower, DF, Pritchard, KI, Hayes, DF, Geyer, CE, Dees, EC, Goetz, MP, Olson, JA, Lively, T, Badve, SS, Saphner, TJ, Wagner, LI, Whelan, TJ, Ellis, MJ, Paik, S, Wood, WC, Ravdin, PM, Keane, MM, Gomez, HL, Reddy, PS, Goggins, TF, Mayer, IA, Brufsky, AM, Toppmeyer, DL, Kaklamani, VG, Berenberg, JL, Abrams, J, Sledge, GW

“…Background: Black race is associated with worse outcomes in localized hormone receptor (HR)-positive breast cancer in population-based and in clinical trial…”
Get full text

Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814 by Albain, KS, Crager, MR, Barlow, WE, Baehner, FL, Bergamaschi, A, Rae, JM, Ravdin, PM, Tripathy, D, Gralow, JR, Livingston, RB, Osborne, CK, Ingle, JN, Pritchard, KI, Davidson, NE, Carey, LA, Cherbavaz, DB, Sing, AP, Shak, S, Hortobagyi, GN, Hayes, DF

“…BACKGROUND: Unique genes and pathways were identified for prognosis on tamoxifen (T, 5 yrs) and prediction on CAF-T vs T in S8814 using whole transcriptome…”
Get full text

Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814 by Albain, KS, Crager, MR, Barlow, WE, Baehner, FL, Bergamaschi, A, Rae, JM, Ravdin, PM, Tripathy, D, Gralow, JR, Livingston, RB, Osborne, CK, Ingle, JN, Pritchard, KI, Davidson, NE, Carey, LA, Cherbavaz, DB, Sing, AP, Shak, S, Hortobagyi, GN, Hayes, DF

“…BACKGROUND: In SWOG-8814A, pts with ER+ node+ breast cancer and low 21 gene recurrence scores (RS) had good prognosis and no CAF benefit, but high RS predicted…”
Get full text

Classical versus new prognostic factors for adjuvant treatment selection based on line software to estimate risk and benefit by Ravdin, PM

Get full text

Prognosis of patients with resected non-small cell lung cancer: Impact of clinical and pathologic variables by Ravdin, Peter M., Davis, Gregory

“…The objective of this study was to determine whether AJCC staging, supplemented by additional clinical and pathologic variables could identify a subpopulation…”
Get full text

Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102 by HUTCHINS, Laura F, GREEN, Stephanie J, RAVDIN, Peter M, LEW, Danika, MARTINO, Silvana, ABELOFF, Martin, LYSS, Alan P, ALLRED, Craig, RIVKIN, Saul E, OSBORNE, C. Kent

“…We evaluated the efficacy of cyclophosphamide, methotrexate, and fluorouracil (CMF) versus cyclophosphamide, doxorubicin, and fluorouracil (CAF) in…”
Get full text

Abstract P5-07-01: Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies by Cherbavaz, DB, Hayes, DF, Qu, K, Crager, MR, Barlow, WR, Goddard, AD, Beasley, EM, Jeong, J, Collin, F, Liu, M-L, Rae, JM, Ravdin, PM, Tripathy, D, Gralow, JR, Livingston, RB, Osborne, CK, Ingle, JN, Pritchard, KI, Davidson, NE, Carey, LA, Sing, AP, Baehner, FL, Hortobagyi, GN, Shak, S, Albain, KS

“…BACKGROUND: We previously reported that low 21 gene Recurrence Scores (RS) identify patients with ER-positive, lymph node-positive breast cancer who may not…”
Get full text

Decreased Use of Adjuvant Breast Cancer Therapy in a Randomized Controlled Trial of a Decision Aid with Individualized Risk Information by Peele, Pamela B., Siminoff, Laura A., Xu, Ying, Ravdin, Peter M.

“…Objective . Oncology patients often seek involvement in their medical consultations. Such involvement is endorsed by most health care providers and mirrored in…”
Get full text

Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy by Ravdin, P M, Siminoff, I A, Harvey, J A

“…A survey of breast cancer survivors in the United States was conducted to define what they had been told about their prognosis and the value of adjuvant…”
Get more information

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer by Ravdin, P M, Burris, 3rd, H A, Cook, G, Eisenberg, P, Kane, M, Bierman, W A, Mortimer, J, Genevois, E, Bellet, R E

“…The purpose of this study was to evaluate the clinical efficacy and safety of docetaxel in patients with metastatic breast cancer (MBC) resistant to…”
Get more information

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer by Valero, V, Jones, S E, Von Hoff, D D, Booser, D J, Mennel, R G, Ravdin, P M, Holmes, F A, Rahman, Z, Schottstaedt, M W, Erban, J K, Esparza-Guerra, L, Earhart, R H, Hortobagyi, G N, Burris, 3rd, H A

“…To evaluate the efficacy and safety of docetaxel in patients with paclitaxel-resistant metastatic breast cancer (MBC). Docetaxel (100 mg/m2) was administered…”
Get more information

Time-dependence of hazard ratios for prognostic factors in primary breast cancer by Hilsenbeck, S G, Ravdin, P M, de Moor, C A, Chamness, G C, Osborne, C K, Clark, G M

“…Some prognostic factors, such as steroid receptors, appear strongly related to outcome in early studies with short follow-up, but as follow-up matures the…”
Get full text

Decision-making in early breast cancer: guidelines and decision tools by Baum, M., Ravdin, P.M.

“…The meta-analysis of trials of adjuvant systemic therapy for early breast cancer provides robust information on the impact of both cytotoxic chemotherapy and…”
Get full text

Prognostic factors in early breast carcinoma by Mansour, E G, Ravdin, P M, Dressler, L

“…Several investigators, the SEER data, and the ECOG/Intergroup study have shown that patients with small tumors (< 0.5 cm) have a recurrence rate of less than…”
Get more information

Managing the risk of osteoporosis in women with a history of early breast cancer by Ravdin, Peter M

“…Estrogen is known to play an important role in skeletal health. Female breast cancer patients who receive treatments that reduce estrogen levels, such as…”
Get more information

Should HER2 status be routinely measured for all breast cancer patients? by Ravdin, P M

“…Several recent publications have re-opened the question of whether HER2 status should be determined for all patients with newly diagnosed breast cancer. The…”
Get more information

Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators by Ravdin, P M, De Laurentiis, M, Vendely, T, Clark, G M

“…If axillary lymph node status of breast cancer patients could be accurately predicted from basic clinical information and from characteristics of their primary…”
Get more information